News
TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.
Satya Nadella has unveiled BioEmu, Microsoft's new AI initiative aimed at accelerating drug discovery processes.
A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...
Microsoft's BioEmu, an AI-driven model, decodes protein motion to enhance drug discovery, offering rapid insights into ...
Microsoft's CEO, Satya Nadella, has announced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding ...
Microsoft's CEO, Satya Nadella, has introduced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding protein motion.
Hiding in Plain Sight Quantum computing has surged from theoretical curiosity to a transformative frontier, promising to ...
TandemAI, a company transforming drug discovery with state-of-the-art AI and physics-based technologies integrated with full wet lab capabilities, and Perpetual Medicines, which is advancing a ...
Researchers discovered how to flip the structure of complex drug compounds using a simple reagent, offering a game-changing ...
Revolution Medicines' proprietary data will train a bespoke version of NeuralPLexer, an AI model for protein-ligand ...
Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 mil | ...
A fundamental discovery by University of Missouri scientists could help solve one of the most frustrating challenges in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results